Scientific Due Diligence
and Commercial Feasibility Report
An investment company owning a stake in a publicly listed biotech company in the field of immunology wanted to get an independent opinion on the performance and potential of the company’s individual development programs. evalueSCIENCE was contracted to perform scientific due diligence on the company's technology and product portfolio.
The therapeutic potential of the company's immune modulating programs in 6 different therapeutic areas was assessed by 7 evalueSCIENCE Experts. While the scientific diligence and commercial feasibility report valued the company’s proprietary technology platform very highly, it was recommended to focus on a single program in the most promising area and to stop or out-license the other programs. The investor handed the report to the company. The report contributed to the company’s decision to focus on this program.